公开(公告)号：US10975153B2

公开(公告)日：2021-04-13

申请号：US15319143

申请日：2015-06-18

Applicant: Five Prime Therapeutics, Inc.

Inventor： Julie Hambleton ,  Emma Masteller ,  James Zanghi ,  Robert Sikorski ,  Hong Xiang

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.

公开(公告)号：US10562970B2

公开(公告)日：2020-02-18

申请号：US15935621

申请日：2018-03-26

Applicant: Five Prime Therapeutics, Inc.

Inventor： Justin Wong ,  Maximiliano Vasquez

IPC: C07K16/28 ,  C12N15/11 ,  C12N15/63 ,  A61K39/395 ,  A61K45/06

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

公开(公告)号：US20190330364A1

公开(公告)日：2019-10-31

申请号：US16476814

申请日：2018-01-10

Applicant: Bristol-Myers Squibb Company ,  Five Prime Therapeutics, Inc.

Inventor： Robert J. Johnston ,  Andrew Rankin ,  Arathi Krishnakumar ,  Paul O. Sheppard ,  Arvind Rajpal

IPC: C07K16/28

Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

公开(公告)号：US20190085080A1

公开(公告)日：2019-03-21

申请号：US16111064

申请日：2018-08-23

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20180215830A1

公开(公告)日：2018-08-02

申请号：US15935621

申请日：2018-03-26

Applicant: Five Prime Therapeutics, Inc.

Inventor： Justin Wong ,  Maximiliano Vasquez

IPC: C07K16/28 ,  C12N15/11 ,  A61K39/395 ,  A61K45/06 ,  C12N15/63

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

公开(公告)号：US20180142016A1

公开(公告)日：2018-05-24

申请号：US15574810

申请日：2016-05-17

Applicant: FIVE PRIME THERAPEUTICS, INC. ,  EUREKA THERAPEUTICS, INC.

Inventor： Brian WONG ,  Emma MASTELLER ,  Cheng LIU ,  Yiyang XU ,  Hong LIU ,  Su YAN ,  Jingyi XIANG ,  Pei WANG

IPC: C07K16/28 ,  A61K47/68 ,  A61K51/10 ,  A61P35/00 ,  A61K38/05 ,  A61P35/02 ,  G01N33/574 ,  C07K16/00

CPC classification number: C07K16/2803 ,  A61K38/05 ,  A61K47/6817 ,  A61K47/6851 ,  A61K47/6881 ,  A61K51/1027 ,  A61K51/1042 ,  A61K51/1096 ,  A61K2039/505 ,  A61P35/00 ,  A61P35/02 ,  C07K16/005 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/57492 ,  G01N2333/912

Abstract: The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.

公开(公告)号：US20160319028A1

公开(公告)日：2016-11-03

申请号：US15152161

申请日：2016-05-11

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Justin Wong ,  Haishan Lin

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2869 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.

公开(公告)号：US20160152715A1

公开(公告)日：2016-06-02

申请号：US14925534

申请日：2015-10-28

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Katherine E. Lewis

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/3046 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

Abstract translation: 提供了与PD-1 / PD-L1抑制剂结合使用结合集落刺激因子1受体（CSF1R）的抗体治疗癌症的方法。

公开(公告)号：US20160106809A1

公开(公告)日：2016-04-21

申请号：US14890047

申请日：2014-05-22

Applicant: FIVE PRIME THERAPEUTICS, INC. ,  GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

Inventor： David Bellovin ,  Kevin Baker ,  Thomas Brennan ,  Arundathy Nirmalini Pandite ,  Bijoyesh Mookerjee ,  Maurice P. DeYoung ,  Rakesh Kumar

IPC: A61K38/17 ,  A61K33/24 ,  A61K31/337 ,  G01N33/574 ,  A61K31/519 ,  C07K14/71 ,  C12Q1/68 ,  A61K45/06 ,  A61K31/555

CPC classification number: A61K38/179 ,  A61K31/337 ,  A61K31/519 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  C07K14/71 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57496 ,  G01N2333/49 ,  G01N2333/50 ,  G01N2333/503 ,  G01N2333/515 ,  G01N2800/52

Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.

Abstract translation: 提供了包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子的癌症治疗方法。 提供了包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子和至少一种抗血管生成剂的治疗癌症的方法。

公开(公告)号：US20160096876A1

公开(公告)日：2016-04-07

申请号：US14877698

申请日：2015-10-07

Applicant: Five Prime Therapeutics, Inc.

Inventor： Lewis T. Williams ,  Elizabeth Bosch ,  Stephen K. Doberstein ,  Kevin Hestir ,  Diane Hollenbaugh ,  Ernestine Lee ,  Minmin Qin ,  Ali Sadra ,  Justin Wong ,  Ge Wu ,  Hongbing Zhang

IPC: C07K14/71

CPC classification number: C07K14/71 ,  A61K45/06 ,  C07K14/765 ,  C07K16/2863 ,  C07K17/08 ,  C07K2319/30 ,  C07K2319/32

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.